tetano
Editor, Senior Moderator
Am J Transplant. 2020 Apr 16. doi: 10.1111/ajt.15929. [Epub ahead of print]
COVID-19 in solid organ transplant recipients: a single-center case series from Spain.
Fern?ndez-Ruiz M[SUP]1[/SUP], Andr?s A[SUP]2[/SUP], Loinaz C[SUP]3[/SUP], Delgado JF[SUP]4,[/SUP][SUP]5[/SUP], L?pez-Medrano F[SUP]1[/SUP], San Juan R[SUP]1[/SUP], Gonz?lez E[SUP]2[/SUP], Polanco N[SUP]2[/SUP], Folgueira MD[SUP]6[/SUP], Lalueza A[SUP]7[/SUP], Lumbreras C[SUP]7[/SUP], Aguado JM[SUP]1[/SUP].
Author information
Abstract
The clinical characteristics, management and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplantation (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 ? 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine [HCQ]) was used in 50.0% of patients, and had to be prematurely discontinued in two of them. Other antiviral regimens included HCQ monotherapy (27.8%) and interferon-β (16.7%). As of April 4, the case fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C reactive protein levels at various points were significantly higher among recipients that experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; coronavirus; outcome; solid organ transplantation; treatment
PMID:32301155DOI:10.1111/ajt.15929
COVID-19 in solid organ transplant recipients: a single-center case series from Spain.
Fern?ndez-Ruiz M[SUP]1[/SUP], Andr?s A[SUP]2[/SUP], Loinaz C[SUP]3[/SUP], Delgado JF[SUP]4,[/SUP][SUP]5[/SUP], L?pez-Medrano F[SUP]1[/SUP], San Juan R[SUP]1[/SUP], Gonz?lez E[SUP]2[/SUP], Polanco N[SUP]2[/SUP], Folgueira MD[SUP]6[/SUP], Lalueza A[SUP]7[/SUP], Lumbreras C[SUP]7[/SUP], Aguado JM[SUP]1[/SUP].
Author information
Abstract
The clinical characteristics, management and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplantation (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 ? 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine [HCQ]) was used in 50.0% of patients, and had to be prematurely discontinued in two of them. Other antiviral regimens included HCQ monotherapy (27.8%) and interferon-β (16.7%). As of April 4, the case fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C reactive protein levels at various points were significantly higher among recipients that experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; coronavirus; outcome; solid organ transplantation; treatment
PMID:32301155DOI:10.1111/ajt.15929